Journal Mobile Options
Table of Contents
Vol. 11, No. 2, 2004
Issue release date: March–April 2004
J Biomed Sci 2004;11:186–199
(DOI:10.1159/000076031)

Glossogyne tenuifolia Acts to Inhibit Inflammatory Mediator Production in a Macrophage Cell Line by Downregulating LPS-Induced NF-κB

Wu M.-J. · Wang L. · Ding H.-Y. · Weng C.-Y. · Yen J.-H.
Departments of aBiotechnology and bCosmetic Science, Chia-Nan University of Pharmacy and Science, and cScinoPharm Biotech Ltd, Tainan Science-Based Industrial Park, Tainan, Taiwan, ROC

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Glossogyne tenuifolia (hsiang-ju) (GT) is a traditional antipyretic herb used in Chinese medicine; however, no information is available to explain its action. The objective of this research was to elucidate the molecular pharmacological activity and the effective components in the ethanol extract of GT. We found that GT had potent anti-inflammatory effects on the lipopolysaccharide (LPS)-activated murine macrophages, RAW264.7. GT downregulated LPS-induced expression of inducible nitric oxide synthase (iNOS) by blocking its transcription. GT also caused a dose-dependent inhibition of the release of prostaglandin E2 by repressing the promoter activity of the inducible cyclooxygenase (COX-2) gene. Moreover, GT exerted a dose-dependent inhibition of the LPS-stimulated release of the proinflammatory cytokines, TNF-α, IL-1β, IL-6, and IL-12. To determine the mechanism by which GT inhibits LPS signaling, we focused on nuclear factor-ĸB (NF-ĸB) activation. Western blot analysis revealed that GT abolished LPS-induced inhibitor-ĸB phosphorylation. The electrophoretic mobility shift assay demonstrated that GT abolished LPS-mediated ĸB DNA binding activity. Moreover, macrophages were transfected with a vector coding for the luciferase reporter gene under the control of NF-ĸB cis-acting elements, and the transfected macrophages showed that the LPS-stimulated luciferase activity was GT-sensitive. These results suggest that GT attenuates inflammatory mediator synthesis of activated macrophages through an NF-ĸB-dependent pathway. The active components of GT were identified as oleanolic acid and luteolin-7-glucoside. Both of these compounds inhibited LPS-stimulated inflammatory mediator production and NF-ĸB activation. We conclude that GT inhibits NF-ĸB-mediated gene expression and downregulates inflammatory mediator production in murine macrophages.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium-based semiautomated colorimetric assay: Assessment of chemosensitivity testing. Cancer Res 47:936–942;1987.
  2. Chen F, Castrnova V, Shi X, Dermers LM. New insights into the role of nuclear factor-kappaB, a ubiquitous transcription factor in the initiation of diseases. Clin Chem 45:7–17;1999.
  3. Chen Z, Hagler J, Palombella VJ, Melandri F, Scherer D, Ballard D, Maniatis T. Signal-induced site-specific phosphorylation targets I kappa B alpha to the ubiquitin-proteasome pathway. Genes Dev 9:1586–1597;1995
  4. Chiou WF, Chen CF, Lin JJ. Mechanisms of suppression of inducible nitric oxide synthase (iNOS) expression in RAW 264.7 cells by andrographolide. Br J Clin Pharmacol 129:1553–1560;2000.
  5. Choi CY, You H, Jeong HG. Nitric oxide and tumor necrosis factor-α production by oleanolic acid via nuclear factor-κB activation in macrophages. Biochem Biophys Res Commun 288:49–55;2001.
  6. Day AJ, Canada FJ, Diaz JC, Kroon PA, Mclauchlan R, Faulds CB, Plumb GW, Morgan MR, Williamson G. Dietary flavonoid and isoflavone glycosides are hydrolysed by the lactase site of lactase phlorizin hydrolase. FEBS Lett 468:166–170;2000.
  7. Day AJ, Depont MS, Ridley S, Rhodes M, Rhodes MJ, Morgan MR, Williamson G. Deglycosylation of flavonoid and isoflavonoid glycosides by human small intestine and liver β-glucuronidase activity. FEBS Lett 436:71–75;1998.
  8. Dinarello CA. Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist. Int Rev Immunol 16:457–499;1998.
  9. Fenton MJ, Golenbock DT. LPS-binding proteins and receptors. J Leukoc Biol 64:25–32;1998.
  10. Fu JY, Masferrer JL, Seibert K, Raz A, Needleman P. The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 265:16737–16740;1990.
  11. Glauser MP. The inflammatory cytokines. New developments in the pathophysiology and treatment of septic shock. Drugs 52(suppl 2):9–17;1996.
  12. Hasko G, Nemeth ZH, Szabo C, Zsilla G, Salzman AL, Vizi ES. Isoproterenol inhibits IL-10, TNF-α, and nitric oxide production in RAW 264.7 macrophages. Brain Res Bull 45:183–187;1998.

    External Resources

  13. Kotlyarov A, Gaesterl M. Is MK2 (mitogen-activated protein kinase-activated protein kinase 2) the key for understanding post-transcriptional regulation of gene expression? Biochem Soc Trans 30:959–963;2002.
  14. Kudoh I, Miyazaki H, Ohara M, Fukushima J, Tazawa T, Yamada H. Activation of alveolar macrophages in acid-injured lung in rats: Different effects of pentoxifylline on tumor necrosis factor-alpha and nitric oxide production. Crit Care Med 29:1621–1625;2001.
  15. Lemay S, Lebedeva TA, Singh AK. Inhibition of cytokine gene expression by sodium salicylate in a macrophage cell line through an NF-κB-independent mechanism. Clin Diagn Lab Immunol 6:567–572;1999.
  16. Liu J. Pharmacology of oleanolic acid and ursolic acid. J Ethnopharmacol 49:57–68;1995.
  17. Luheshi GN. Cytokines and fever. Mechanisms and sites of action. Ann NY Acad Sci 856:83–89;1998
  18. Nathan C. Natural resistance and nitric oxide. Cell 82:873–876;1995.
  19. Nathan C, Xie QW. Nitric oxide synthase: Roles, tolls, and controls. Cell 78:915–918;1994.
  20. Picot D, Loll PJ, Garavito RM. The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature 367:243–249;1994.
  21. Rao KM. Molecular mechanisms regulating iNOS expression in various cell types. J Toxicol Environ Health B Crit Rev 3:27–58;2000.
  22. Shi MM, Godleski JJ, Paulauskis JD. Regulation of macrophage inflammatory protein-1α mRNA by oxidative stress. J Biol Chem 271:5878–5883;1996.
  23. Sun Z, Andersson R. NF-kappaB activation and inhibition: A review. Shock 18:99–106;2002.
  24. Tracey KJ. Tumor necrosis factor (cachetin) in the biology of septic shock syndrome. Circ Shock 35:123–128;1991.
  25. Tracey KJ, Wei H, Manogue KR, Fong Y, Hesse DG, Nguyen HT, Kuo GC, Beutler B, Cotran RS, Cerami A. Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation. J Exp Med 167:1211–1227;1998.
  26. Wadleigh DJ, Reddy ST, Kopp E, Ghosh S, Herschman HR. Transcriptional activation of the cyclooxygenase-2 gene in endotoxin-treated RAW 264.7 macrophages. J Biol Chem 275:6259–6266;2000.
  27. Xagorari A, Papapetropoulos A, Mauromatis A, Economou M, Fotsis T, Roussos C. Luteolin inhibits an endotoxin-stimulated phosphorylation cascade and proinflammatory cytokine production in macrophages. J Pharmacol Exp Ther 296:181–187;2001.
  28. Xagorari A, Roussos C, Papapetropoulos A. Inhibition of LPS-stimulated pathways in macrophages by the flavonoid luteolin. Br J Pharmacol 136:1058–1064;2002.
  29. Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J Clin Invest 107:135–142;2001.
  30. Zingarelli B, Sheehan M, Wong H. Nuclear factor-[kappa]B as a therapeutic target in critical care medicine. Crit Care Med 31:S105–S111;2003.

    External Resources



Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50